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ABSTRACT
Endothelial colony forming cells (ECFCs) represent a population of truly 
endothelial precursors that promote the angiogenic switch in solid tumors, such as 
breast cancer (BC). The intracellular Ca2+ toolkit, which drives the pro-angiogenic 
response to VEGF, is remodelled in tumor-associated ECFCs such that they are 
seemingly insensitive to this growth factor. This feature could underlie the relative 
failure of anti-VEGF therapies in cancer patients. Herein, we investigated whether 
and how VEGF uses Ca2+ signalling to control angiogenesis in BC-derived ECFCs (BC-
ECFCs). Although VEGFR-2 was normally expressed, VEGF failed to induce proliferation 
and in vitro tubulogenesis in BC-ECFCs. Likewise, VEGF did not trigger robust Ca2+ 
oscillations in these cells. Similar to normal cells, VEGF-induced intracellular Ca2+ 
oscillations were triggered by inositol-1,4,5-trisphosphate-dependent Ca2+ release 
from the endoplasmic reticulum (ER) and maintained by store-operated Ca2+ 
entry (SOCE). However, InsP3-dependent Ca2+ release was significantly lower in  
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BC-ECFCs due to the down-regulation of ER Ca2+ levels, while there was no remarkable 
difference in the amplitude, pharmacological profile and molecular composition 
of SOCE. Thus, the attenuation of the pro-angiogenic Ca2+ response to VEGF was 
seemingly due to the reduction in ER Ca2+ concentration, which prevents VEGF 
from triggering robust intracellular Ca2+ oscillations. However, the pharmacological 
inhibition of SOCE prevented BC-ECFC proliferation and in vitro tubulogenesis. These 
findings demonstrate for the first time that BC-ECFCs are insensitive to VEGF, which 
might explain at cellular and molecular levels the failure of anti-VEGF therapies in BC 
patients, and hint at SOCE as a novel molecular target for this disease.
INTRODUCTION
Breast cancer (BC) consists in a heterogeneous 
group of malignancies deriving from the epithelial cells 
lining the milk ducts and still represents the leading cause 
of cancer-related mortality in women worldwide [1]. BC 
growth and metastasis are supported by the development 
of an intricate network of blood vessels which nourish 
cancer cells with oxygen and nutrients and remove their 
catabolic waste [2]. An increase in microvascular density 
positively correlates with the degree of metastasis, tumor 
recurrence and poorer outcome of invasive BC [3], which 
further hints at neovascularisation as a key determinant 
of BC malignancy. Vascular endothelial growth factor 
(VEGF) comprises a family of secreted polypeptides 
which include VEGF-A, VEGF-B, VEGF-C, VEGF-D 
and placental growth factor (PLGF) and act through 
three cognate receptor tyrosine kinases, designated as 
VEGFR1 (Flt1), VEGFR2 (Flk1/KDR), and VEGFR3 
(Flt4) [4]. VEGF-A (hereafter termed as VEGF) is the 
prototypical member of the family and constitutes a master 
regulator of vascular development in health and disease 
[4–6]. VEGFR2 serves as the main transducer of VEGF 
signalling on endothelial cell differentiation, proliferation, 
migration and tubulogenesis [4]. Consistently, targeting 
VEGFR2 with either humanized monoclonal antibodies, 
such as bevacizumab and VEGF-Trap, or tyrosine 
kinase inhibitors (TKIs), such as sorafenib, sunitinib and 
pazopanib, halted neovessel formation and caused tumor 
shrinkage in immunodeficient mouse models of most 
malignancies [7, 8], including BC. Regrettably, these 
promising observations did not translate into an effective 
therapeutic benefit for cancer patients. Clinical trials 
have shown that anti-VEGF drugs, administered either 
as monotherapy or in combination with chemotherapy or 
radiation therapy, merely slowed down tumor progression, 
significantly prolonging only progression free survival 
(PFS), without improving overall survival (OS) in these 
individuals [7, 8]. A recent meta-analysis of randomised 
phase II and III clinical trials of bevacizumab (Avastin) 
revealed a lack of any substantial OS benefit either in the 
neoadjuvant or in the metastatic setting in BC patients [9]. 
Moreover, in 2010, the Food and Drug Administration 
(FDA) removed approval of Avastin for metastatic BC 
because of its toxicity and disease progression during 
long-term treatment [10]. The efficacy of anti-angiogenic 
therapy is severely limited by the development of 
refractoriness to anti-VEGF drugs, which causes tumor 
relapse after an initial period of tumor shrinkage or 
stasis. Also, a minority of cancer patients are intrinsically 
resistant to angiogenesis blockade, such that disease 
progression continues unabated and leads to patient death 
[11]. The failure of anti-VEGF drugs has been attributed 
to several mechanisms, such as the recruitment of VEGF-
insensitive endothelial progenitor cells (EPCs), which are 
mobilized from either the bone marrow or the arterial wall 
and support angiogenesis in several types of cancer [12, 
13], including BC. Among the several EPC subsets that 
have described in peripheral blood, endothelial colony 
forming cells (ECFCs) represent the only truly endothelial 
precursors [14], anastomose with the host vasculature and 
form patent vessels in vivo [14, 15], display an innate 
tumor tropism [13, 16–18] and may therefore drive the 
angiogenic switch by supplying endothelial cells to 
growing neovessels in BC and many other types of tumors, 
including BC [19–21]. A recent study revealed that ECFC 
frequency is remarkably increased in peripheral blood 
of naïve, i.e. not treated, BC patients [22]. Interestingly, 
VEGF fails to stimulate proliferation and in vitro 
tubulogenesis in ECFCs isolated from subjects suffering 
from solid tumors [23], such as renal cell carcinoma 
(RCC) [24] and infantile hemangioma (IH) [25], as well as 
in primary myelofibrosis (PMF) [26]. The effect of VEGF 
on BC-associated ECFCs (BC-ECFCs) is, however, still 
unknown.
VEGF has recently been shown to stimulate 
ECFC proliferation by inducing repetitive oscillations in 
intracellular Ca2+ concentration ([Ca2+]i) [27–29], which in 
turn promote the nuclear translocation of the Ca2+-sensitive 
transcription factor, NF-κB. Upon binding to its agonist, 
VEGFR2 recruits phospholipase Cγ (PLCγ) to synthesize 
inositol-1,4,5-trisphosphate (InsP3), which triggers the 
rhythmical Ca2+ discharge from the endoplasmic reticulum 
(ER), the largest Ca2+ reservoir in ECFCs [30]. VEGF-
induced Ca2+ oscillations are sustained over time by the 
so-called store-operated Ca2+ entry (SOCE) mechanism 
[28], which is initiated by the activation of the ER Ca2+ 
sensor Stim1 following InsP3-induced ER Ca
2+ depletion 
[31]. Once activated, Stim1 translocates towards the most 
peripheral regions of ER, where it traps and gates the two 
ubiquitous store-operated Ca2+-permeable channels, Orai1 
and Transient Receptor Channel Canonical 1 (TRPC1) 
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[24, 31, 32]. The Ca2+ toolkit is severely dysregulated in 
tumor-associated ECFCs [23, 27, 33, 34]]. For instance, 
the ER Ca2+ content is significantly reduced in RCC- 
and IH-derived ECFCs (RCC-ECFCs and IH-ECFCs, 
respectively) [25, 35], which might prevent VEGF from 
eliciting the periodical Ca2+ release [23]. Conversely, 
SOCE is up-regulated and controls proliferation in 
both RCC-ECFCs [24] and IH-ECFCs [25], thereby 
standing out as an alternative, promising target for 
highly angiogenic tumors [33, 36]. Of note, preliminary 
results indicated that VEGF-induced pro-angiogenic Ca2+ 
oscillations could be attenuated also in BC-ECFCs [22].
The present investigation was endeavoured to 
assess whether and how VEGF stimulates pro-angiogenic 
Ca2+ oscillations in BC-ECFCs. We exploited a multi-
disciplinary approach, comprising electron microscopy 
(EM), Ca2+ imaging, real-time polymerase chain reaction 
(qRT-PCR), Western blotting, and functional assays to 
demonstrate that VEGF fails to promote proliferation and 
in vitro tubulogenesis in BC-ECFCs due to the down-
regulation of the underlying repetitive Ca2+ spikes. The 
suppression of the Ca2+-dependent response to VEGF 
involves the decrease in ER Ca2+ levels. Conversely, 
SOCE is still functional in these cells and can be targeted 
to inhibit BC-ECFC proliferation. Our data contribute to 
shed light at cellular and molecular level on the failure of 
anti-VEGF therapies and hint at SOCE as an alternative 
target to halt vascularization in this disease.
RESULTS
Ultrastructural analysis reveals that BC-ECFCs 
are morphologically different as compared to 
normal cells
A recent microarray analysis unveiled that the 
genomic profile of BC-ECFCs was dramatically altered 
as compared to normal cells (N-ECFCs) as indicated by 
the identification of 342 differentially expressed genes 
(DEGs; 192 up-regulated, 150 down-regulated) in the 
former [22]. In order to assess whether this remarkable 
difference in the gene signature was associated to a 
significant ultrastructural rearrangement, as recently 
shown for RCC-ECFCs [35], we carried out a throughout 
analysis at electron microscope levels. This investigation 
revealed clear ultrastructural differences between N- and 
BC-ECFCs. Figure 1A and Figure 1D show that smooth 
ER (sER) vesicles were more abundant in BC-ECFCs. 
Likewise, rough ER (rER) cisternae occupied a much 
larger area and were more closely packed in BC-ECFCs 
as compared to normal cells (Figure 1B and Figure 
1E). Finally, mitochondria were also more numerous 
Figure 1: Ultrastructural remodelling in breast cancer-derived endothelial colony forming cells. Ultrastructural analysis 
of endothelial colony forming cell morphology. Representative images of two N-ECFCs and two BC-ECFCs samples analyzed. The bars 
in (A-F) correspond to 500 nm.
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and enlarged in BC-ECFCs (Figure 1C and Figure 1F). 
Therefore, not only the gene signature profile [22], but 
also the cellular microarchitecture was dramatically 
remodeled in BC-ECFCs.
VEGF does not stimulate proliferation and 
in vitro tubulogenesis in BC-ECFCs
We have widely shown that 10 ng/mL is the most 
effective concentration to promote VEGF-dependent 
proliferation and in vitro tubulogenesis in ECFCs [26, 
28, 29, 37]]. Both N- and BC-ECFCs were plated in the 
presence of EBM-2 supplemented with 2% foetal calf 
serum and 10 ng/mL VEGF, as described elsewhere [26]. 
Under such conditions, N-ECFCs reached confluence after 
5 days in culture, while BC-ECFCs did not undergo any 
significant (p<0.05) increase in the rate of cell growth 
(Figure 2A). Neither N-ECFCs nor BC-ECFCs replicated 
in the absence of VEGF, while serum starvation did not 
affect the proliferative response to VEGF in N-ECFCs 
(data not shown). We further investigated the physiological 
outcome of VEGF by carrying out a tube formation assay 
in Matrigel, which reconstitutes the basement membrane 
extracellular matrix. This assay recapitulates many 
steps of the angiogenic process, including adhesion, 
migration, protease activity, and tubule formation, and 
is, therefore, extremely useful to evaluate whether VEGF 
differently affects N- and BC-ECFCs [22, 24, 26]. Ten 
ng/mL VEGF stimulated N-ECFCs to assemble into an 
extended bidimensional capillary-like network, while 
it was ineffective on BC-ECFCs (Figure 2B and Figure 
2C). These data clearly show that VEGF stimulates 
proliferation and in vitro tubulogenesis in N-ECFCs, but 
not BC-ECFCs. In order to assess whether the distinct 
effect of VEGF was associated to the down-regulation 
of VEGFR-2 in tumor-associated cells, we analyzed its 
expression in both types of cells through flow cytometry, 
as shown in [24]. However, no significant difference was 
observed between N- and BC-ECFCs, as depicted in 
Figure 2D and in Supplementary Figure 1. Therefore, the 
Figure 2: VEGF does not stimulate proliferation in breast cancer-derived endothelial colony forming cells. (A), 
mean±SE of ECFCs counted after five days in culture in the presence of EBM-2 + VEGF (10 ng/mL). The results are representative of 
three different experiments conducted on cells harvested from three different donors. VEGF stimulated proliferation in N-ECFCs, but not 
BC-ECFCs. EBM-2 alone, which was used as control, did not induce proliferation either in N- or BC-ECFCs. (B-C), statistical analysis of 
the dimensional (total TLSs/picture) and topologic (total number of meshes/picture) parameters of the capillary-like network established by 
N- and BC-ECFCs, respectively, plated in Matrigel scaffolds. In vitro angiogenesis was stimulated by plating the cells in the presence of the 
EBM-2 medium (which is devoid of growth factors) supplemented with VEGF (10 ng/mL), while EBM-2 alone was used as a control. The 
results are representative of three different experiments conducted on ECFCs deriving from three different donors. The asterisk indicates 
p<0.05. (D), mean±SE of the percentage of ECFCs expressing VEGFR-2, as assessed by flow cytometry. There was no statistically relevant 
difference between N- and BC-ECFCs.
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inability of VEGF to stimulate proliferation in BC-ECFCs 
is likely to involve the downregulation of VEGFR2 
signalling in tumor-associated ECFCs [13, 23].
VEGF-induced intracellular Ca2+ oscillations are 
down-regulated in BC-ECFCs
As mentioned earlier, the mitogenic effect of VEGF 
impinges on the onset of intracellular Ca2+ oscillations, 
which develop with some delay after addition of the 
growth factor [26, 28, 29]. Consistent with our preliminary 
results [22], 10 ng/mL VEGF triggered a detectable 
increase in [Ca2+]i also in BC-ECFCs (Figure 3), while 
there was no spontaneous Ca2+ activity in absence of the 
agonist (not shown). The percentage of responding cells 
was 36.9±10.2% (n=477), which was significantly lower 
(p=0.00339) as compared to that measured in N-ECFCs 
(99.3±0.7%, n=380). The Ca2+ response recorded in BC-
ECFCs consisted in either transient Ca2+ peaks or short, 
asynchronous Ca2+ oscillations, which did not arise 
in phase among the neighbouring cells from a given 
microscopic field (Figure 3). This feature represents 
the hallmark of VEGF-induced Ca2+ oscillations in both 
ECFCs [27] and mature endothelial cells [38]. Each 
Figure 3: VEGF induces intracellular Ca2+ oscillations in breast cancer-derived endothelial colony forming cells. VEGF 
(10 ng/mL) elicits heterogeneous repetitive Ca2+ transients in five BC-ECFCs recorded from the same microscopic field. The dashed box in 
the lowermost trace marks the pacemaker increase in [Ca2+]i that features InsP3-dependent Ca
2+ spikes. In these and the other figures, VEGF 
has been administrated during the time period indicated by the black bars placed above the Ca2+ traces.
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baseline Ca2+ transient was preceded by a slow increase 
in [Ca2+]i (see inset in Figure 3), which is known as 
pacemaker Ca2+ rise and is indicative of InsP3-dependent 
Ca2+ release during the spiking response to VEGF 
[28]. The oscillating response to VEGF was reversibly 
abolished by removing the agonist from the perfusate 
(Figure 4A). When compared to N-ECFCs (Figure 4B), 
a careful statistical analysis revealed that the percentage 
of oscillating cells (Figure 4C) and the amplitude 
(Figure 4E) of the first Ca2+ transient were significantly 
(p<0.05) smaller in BC-ECFCs as compared to healthy 
cells. Conversely, the latency of the Ca2+ response was 
significantly (p<0.05) longer in BC-ECFCs (Figure 
4D). We then exploited a recently described home-made 
software based on wavelet analysis to extract information 
encoded within the complex spatio-temporal pattern 
of Ca2+ spikes and obtain a straightforward quantitative 
evaluation of the differences between VEGF-induced 
Ca2+ oscillations in N- and BC-ECFCs [26, 39, 40]. This 
analysis confirmed that the spiking response to VEGF was 
significantly (p>0.05) reduced in BC-ECFCs (Figure 4F). 
Taken together, these data suggest that the down-regulation 
Figure 4: VEGF-induced intracellular Ca2+ oscillations are weaker in breast cancer-derived endothelial colony 
forming cells. (A), VEGF (10 ng/mL) removal from the bath reversibly inhibited the Ca2+ response to VEGF in BC-ECFCs. (B), VEGF-
induced intracellular Ca2+ oscillations in N- and BC-ECFC. VEGF was applied at 10 ng/mL to both cell types. In the following panels, bar 
histograms have been used to compare the fraction of oscillating cells (C), the latency to the first spike (D), the magnitude of the initial Ca2+ 
transient (E) and the oscillatory index (F) between N- and BC-ECFCs. The asterisk indicates p<0.05.
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of intracellular Ca2+ oscillations underpins the little, if any, 
pro-angiogenic effect of VEGF in BC-ECFCs.
VEGF-induced intracellular Ca2+ oscillations 
require InsP3-dependent Ca2+ release and 
SOCE in BC-ECFCs
The spiking response to VEGF is shaped by the 
concerted interplay between InsP3-dependent Ca
2+ release 
and SOCE in N-ECFCs [28], however, this mechanism is 
subtly remodelled in PMF-derived cells [26]. In order to 
decipher the molecular underpinnings of VEGF-induced 
Ca2+ oscillations in BC-ECFCs, we first challenged the 
cells with the growth factor upon removal of Ca2+ from 
the perfusate (0Ca2+). Unlike cells bathed in the presence 
of extracellular Ca2+ (Figure 5A), VEGF still induced 1-2 
Ca2+ transients in the absence of extracellular Ca2+, but the 
Ca2+ activity rapidly subsided despite for the prolonged 
Figure 5: VEGF-induced intracellular Ca2+ oscillations are triggered by endogenous Ca2+ release and maintained by 
store-operated Ca2+ entry. (A), intracellular Ca2+ oscillations evoked by VEGF (10 ng/mL) in the presence of extracellular Ca2+. (B), 
VEGF induced only 2 Ca2+ spikes in the absence of extracellular Ca2+ (0Ca2+), whereas Ca2+ oscillations resumed upon Ca2+ re-addition 
to the extracellular solution. In the following panels, bar histograms have been used to compare the latency to the first spike (C) and the 
magnitude of the initial Ca2+ transient (D) under 0Ca2+ conditions or preincubation with BTP2 (20 μM, 30 min), which selectively inhibits 
SOCE in ECFCs. The asterisk indicates p<0.05. (E), removal of extracellular Ca2+ (0Ca2+) caused a reversible inhibition of ongoing VEGF-
induced Ca2+ oscillations. VEGF was administered at 10 ng/mL. (F), BTP2 (20 μM, 30 min), a selective SOCE inhibitor, did not prevent 
the onset of VEGF-induced intracellular Ca2+ oscillations, but curtailed their duration to 1-2 transients.
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exposure to the agonist (Figure 5B). The latency of the 
first Ca2+ transient was significantly (p<0.05) longer 
under 0Ca2+ conditions (Figure 5C), while there was 
no statistically relevant difference in its amplitude 
(Figure 5D). Ca2+ oscillations readily resumed upon Ca2+ 
restitution to the bath, thereby showing that the Ca2+ signal 
was initiated by Ca2+ mobilization from the intracellular 
stores and sustained by Ca2+ entry across the plasma 
membrane (Figure 5B). In agreement with this notion, 
removal of external Ca2+ reversibly suppressed ongoing 
VEGF-induced Ca2+ oscillations (Figure 5E). Therefore, 
we then focussed on the PLCγ/InsP3 signalling pathway, 
which underlies periodic ER Ca2+ release in N-ECFCs 
[28]. VEGF failed to ignite the Ca2+ train in the presence 
of U73122 (10 μM, 10 min) (1-[6-[[(17b)-3-methoxyestra-
1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-
dione) (Figure 6A), an aminosteroid which selectivity 
inhibits PLC activity in ECFCs [26, 28, 29], while its 
inactive structural analogue U73343 (10 μM, 10 min) 
failed to block the Ca2+ response (Figure 6A). Likewise, 
2-aminoethoxydiphenyl borate (2-APB; 50 μM, 20 min), 
a widely employed blocker of InsP3 receptors (InsP3Rs), 
suppressed VEGF-induced Ca2+ oscillations (Figure 
6B). As 2-APB may also interfere with Stim1, Orai and 
TRP Vanilloid (TRPV) channels [36], these experiments 
were performed under 0Ca2+ conditions to prevent any 
contaminating effect from Ca2+ influx [28]. Finally, 
VEGF was applied after depletion of the ER Ca2+ pool 
with cyclopiazonic acid (CPA), which selectively inhibits 
the activity of Sarco-Endoplasmic Reticulum Ca2+-
ATPase (SERCA), thereby preventing Ca2+ sequestration 
and emptying the endogenous Ca2+ stores [28]. As shown 
in Figure 6C, VEGF failed to increase intracellular Ca2+ 
levels following 30 min preincubation with CPA in the 
absence of extracellular Ca2+ (0Ca2+). The statistical 
analysis of these data has been synthesized in Figure 6D. 
SOCE represents the most important pathway for Ca2+ 
entry in N-ECFCs [27, 37]. Therefore, we assessed its 
contribution to the maintenance of VEGF-induced Ca2+ 
oscillations by pre-incubating the cells with BTP2 (N-(4-
[3,5-bis(trifluoromethyl)-1H-pyrazo l-1-yl]phenyl)-4-
methyl-1,2,3-thiadiazol e-5-carboxamide) (20 μM, 30 
min), a pyrazole derivative which selectively inhibits 
SOCE in both ECFCs [31, 37] and a growing number of 
Figure 6: VEGF-induced intracellular Ca2+ oscillations are initiated by the PLCγ/InsP3 pathway in breast cancer-
derived endothelial colony forming cells. (A), U73122 (10 μM, 10 min), a selective PLC blocker, prevented the Ca2+ response to 
VEGF, while U73343 (10 μM, 10 min), an inactive analogue of U7322, was without effect. (B), 2-APB (50 μM, 20 min), an InsP3R blocker, 
suppressed VEGF-induced Ca2+ oscillations under 0Ca2+ conditions to prevent any contaminating effect on plasmalemmal channels. (C), 
the depletion of the InsP3-sensitive ER Ca
2+ store with CPA (10 μM) in the absence of external Ca2+ (0Ca2+) prevented the following Ca2+ 
response to VEGF (10 ng/mL). Note the transient increase in [Ca2+]i caused by CPA due to the depletion of the ER Ca
2+ pool. (D), mean±SE 
of the percentage of BC-ECFCs responding to VEGF (10 ng/mL) under the designated treatments. The asterisk indicates p<0.05. NoR: No 
response.
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cell types [41, 42]. This treatment did not prevent the onset 
of the Ca2+ response to VEGF, but curtailed its duration 
to 1-2 Ca2+ spikes (Figure 5F), thereby mimicking the 
effect of 0Ca2+. Unlike 0Ca2+ conditions, however, BTP2 
did not affect the latency of the first Ca2+ transient (Figure 
5C), as well as it did not reduce its amplitude (Figure 
5D). Overall, these observations clearly show that VEGF-
induced Ca2+ oscillations required the InsP3-dependent 
rhythmical ER Ca2+ discharge and were sustained by 
SOCE also in BC-ECFCs. Therefore, the downregulation 
of the Ca2+-dependent pro-angiogenic response to VEGF 
in these cells must involve the remodeling of one or more 
components of their Ca2+ toolkit.
The ER Ca2+ content is decreased, while SOCE is 
unaffected, in BC-ECFCs
In order to assess whether and how the intracellular 
Ca2+ handling is altered in BC-ECFCs, we exploited the 
“Ca2+ add-back” protocol, which consists in first depleting 
the ER Ca2+ pool with CPA (10 μM) in the absence of 
extracellular Ca2+ (0Ca2+) and then restoring extracellular 
Ca2+ to monitor the following SOCE [24, 25]. This 
protocol has been largely used to assess both the ER Ca2+ 
content and the extent of SOCE activation in a myriad of 
cancer cells [43, 44], including tumor-associated ECFCs 
[26, 39, 40]. We found that CPA-induced ER Ca2+ release 
was significantly (p<0.05) reduced as compared to 
N-ECFCs, while SOCE amplitude was unaffected (Figure 
7A and Figure 7B). To further corroborate these data, we 
repeated the “Ca2+ add-back” protocol in the presence of 
the physiological autacoid, ATP (100 μM), which binds to 
metabotropic P2Y receptors to stimulate InsP3 synthesis 
and promote InsP3-dependent ER Ca
2+ release [26, 39, 
40]. Again, ATP-induced InsP3-dependent ER Ca
2+ release 
was significantly (p<0.05) lower in BC-ECFCs, while 
ATP-induced SOCE was unaltered as respect to N-ECFCs 
(Figure 7C and Figure 7D). As previously described [24], 
ATP was removed from the extracellular solution 100 sec 
before Ca2+ re-addition to prevent Ca2+ entry across store-
independent pathways (Figure 7C). The reduction in ATP-
induced intracellular Ca2+ release was not due to the down-
regulation of InsP3Rs, as qRT-PCR analysis carried out by 
using the specific primers described in Supplementary 
Table 1  showed that there was no statistically relevant 
difference in the expression of all InsP3R isoforms 
between N- and BC-ECFCs (Supplementary Figure 
2). Collectively, these data concur with the preliminary 
Figure 7: Remodelling of the Ca2+ toolkit in breast cancer-derived endothelial colony forming cells. (A), the intracellular 
Ca2+ pool was depleted by stimulating the cells with CPA (10 μM) in the absence of external Ca2+ (0Ca2+), and Ca2+ influx through store-
operated channels was then assessed on Ca2+ replenishment to the bathing solution. (B), mean±SE of the amplitude of CPA-induced Ca2+ 
release and CPA-induced SOCE in N- and BC-ECFCs. The asterisk indicates p<0.05. (C), ATP (100 μM) evoked a transient increase in 
[Ca2+]i in N- and BC-ECFCs bathed in the absence of external Ca
2+ (0Ca2+). (D) ATP was then removed from the bath, while Ca2+ was 
readded to the perfusate in order to measure SOCE. F, mean±SE of the amplitude of ATP-induced Ca2+ release and ATP-induced SOCE 
recorded from both N- and BC-ECFCs. The asterisk indicates p<0.05.
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data we recently reported [22] and strongly suggest that 
the Ca2+ signalling toolkit is partially remodelled in BC-
ECFCs. This dysregulation consists in a dramatic drop in 
ER Ca2+ levels, which might prevent the InsP3-dependent 
ER Ca2+ cycling that underlies the pro-angiogenic response 
to VEGF.
The pharmacological profile and molecular 
composition of SOCE is similar to that described 
in N-ECFCs
In order to confirm that BTP2 selectively inhibits 
agonist-induced SOCE in BC-ECFCs, we carried out the 
“Ca2+ add-back” protocol in the presence of this drug. 
BTP2 (20 μM, 30 min) selectively blocked both CPA- 
and ATP-induced SOCE, while it did not affect the initial 
phase of intracellular Ca2+ mobilization (Figure 8A–8D). 
The same effect was achieved by the trivalent cation, 
La3+ (10 μM, 30 min) (Figure 9A–9D). As discussed 
elsewhere [36, 37, 45], BTP2 and low micromolar doses 
of lanthanides specifically target store-operated channels 
(SOCs) whose pore-forming subunits are provided by 
Orai1 and/or TRPC1. These data further corroborate the 
notion that both passive CPA-facilitated and active InsP3-
mediated ER Ca2+ store depletion led to the activation 
of the same plasmalemmal Ca2+-permeable pathway in 
ECFCs [23, 27]. Recent studies showed that Orai3 may 
replace Orai1 as pore-forming of store-operated channels 
[36, 43, 46]. To assess this issue in BC-ECFCs, we took 
advantage from the biphasic dependence of Orai1 on 
2-APB. 2-APB activates Orai1 at 5 μM, while inhibits it 
at concentrations higher than 30 μM [24, 36]. Therefore, 
we fully activated SOCE by challenging BC-ECFCs with 
thapsigargin (2 μM), another SERCA inhibitor structurally 
unrelated to CPA, in the presence of extracellular Ca2+. 
As shown in RCC-ECFCs [24], this treatment caused a 
sustained increase in [Ca2+]i which was due to both passive 
ER Ca2+ release and SOCE. The following addition of 5 
μM 2-APB caused a further increase in [Ca2+]i, which 
was in turn suppressed by the subsequent application of 
50 μM 2-APB in 61 cells (Figure 10). This data further 
corroborates the role of Orai1 in SOCE activation in BC-
ECFCs.
To extend this information at molecular level, we 
investigated the expression of the molecular components 
of SOCE through both qRT-PCR and immunoblotting. The 
expression of Stim1-2, Orai1-3, TRPC1-7 transcripts was 
assessed by qRT-PCR analysis of mRNA extracts from 
Figure 8: BTP2 inhibits store-dependent Ca2+ entry in breast cancer-derived endothelial colony forming cells. (A), CPA-
elicited SOCE in the absence and presence of BTP2 (20 μM). The cells were pre-incubated with the drug for 30 min before the beginning 
of the experimental protocol. CPA was administered at 10 μM. (B), mean±SE of the amplitude of CPA-induced intracellular Ca2+ release 
and CPA-induced SOCE in the absence and presence of BTP2. The asterisk indicates p<0.05. (C), ATP-evoked intracellular Ca2+ release 
and SOCE in the presence and absence of BTP2 (20 μM). The cells were pre-incubated with the drug for 30 min before the beginning of the 
experimental protocol. ATP was applied at 100 μM. (D), mean±SE of the amplitude of CPA-induced Ca2+ release and CPA-induced SOCE 
in the absence and presence of BTP2. The asterisk indicates p<0.05.
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N- and BC-ECFCs, as previously shown [24, 25, 47]. We 
utilized the specific primers described in Supplementary 
Table 2, whereas negative controls were conducted 
by omitting the reverse transcriptase (not shown). The 
housekeeping gene β-actin served as reference gene for 
data normalization. We found that only Stim1 (Figure 
11A) was significantly (p<0.05) up-regulated in BC-
ECFCs as compared to N-ECFCs, while there was no 
remarkable difference in the pattern of expression of Stim2 
(Figure 11B), Orai1 (Figure 11C), Orai2 (Figure 11D) and 
Orai3 (Figure 11E). Also, TRPC1 mRNA levels did not 
differ between N- and BC-ECFCs, while TRPC4 was 
Figure 9: La3+ inhibits store-dependent Ca2+ entry in breast cancer-derived endothelial colony forming cells. (A), CPA-
elicited SOCE in the absence and presence of La3+ (10 μM). The cells were pre-incubated with the drug for 20 min before the beginning 
of the experimental protocol. CPA was administered at 10 μM. (B), mean±SE of the amplitude of CPA-induced intracellular Ca2+ release 
and CPA-induced SOCE in the absence and presence of La3+. The asterisk indicates p<0.05. (C), ATP-evoked intracellular Ca2+ release 
and SOCE in the presence and absence of La3+ (10 μM). The cells were pre-incubated with the drug for 30 min before the beginning of the 
experimental protocol. ATP was applied at 100 μM. (D), mean±SE of the amplitude of CPA-induced Ca2+ release and CPA-induced SOCE 
in the absence and presence of BTP-2. The asterisk indicates p<0.05.
Figure 10: 2-APB exerts a dose-dependent effect on store-operated Ca2+ entry in breast cancer-derived endothelial 
colony forming cells. 5 μM 2-APB enhanced SOCE induced by thapsigargin (2 μM), whereas 50 μM inhibited it. This is a pharmacological 
property of Orai1 containing store-operated channels.
Oncotarget95234www.impactjournals.com/oncotarget
significantly (p<0.05) over-expressed in tumor-associated 
cells (Figure 11F and Figure 11G). Similar to N-ECFCs, 
BC-ECFCs lacked TRPC2, TRPC3, TRPC5, TRPC6 and 
TRPC7 (data not shown). These data were confirmed at 
protein levels by a Western blot analysis performed by 
using affinity-purified antibodies directed against Stim1, 
Orai1, TRPC1 and TRPC4 (Figure 12). Immunoblots 
revealed a major band of 33 kDa for Orai1 and of 110 
kDa for TRPC1 in both cell types, whereas the anti-Stim1 
antibody detected two bands of 100 kDa and 77 kDa only 
in BC-ECFCs. Stim1 was detected as a double also in 
RCC-ECFCs [24], several human BC and RCC cell lines 
[43, 48], and primary cultures of human mestatic RCC 
cell lines [49]. Densitometric analysis of the gels showed 
that Stim1 protein was up-regulated in BC-ECFCs, while 
Orai1 and TRPC1 proteins were equally expressed in both 
cell types. Similar to Stim1, immunoblotting revealed a 
single band of 110 kDa for TRPC4 (Figure 12D), which 
was significantly (p<0.05) up-regulated compared to 
N-ECFCs. Taken together, these findings demonstrate that: 
1) the pharmacological profile and molecular composition 
of SOCE in BC-ECFCs is similar to that described in 
Figure 11. The expression of Stim1-2, Orai1-3, TRPC1 and TRPC4 transcripts in breast cancer-derived endothelial 
colony forming cells. qRT-PCR showing increased expression of Stim1 (A) mRNA in BC-ECFCs compared to N-ECFCs. Conversely, 
Stim2 (B), Orai1 (C), Orai2 (D), Orai3 (E), TRPC1 (F), were not differently expressed in BC-ECFCs. Also, the expression of TRPC4 
mRNA was enhanced in BC-ECFCs (G). Bars represent mean±SE of at least 4 different experiments each from different RNA extracts. The 
asterisk indicates p<0.05 vs. N-ECFCs (ANOVA followed by Newman-Keuls’ Q test). The PCR products were of the expected size (not 
shown): Orai1, 257 bp; Orai2, 334 bp; Orai3, 159 bp; Stim1, 347 bp; Stim2, 186 bp; TRPC1, 307 bp and TRPC4, 300 bp.
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N-ECFCs; and 2) the attenuation of VEGF-induced Ca2+ 
oscillations is unlikely to involve the recruitment of an 
alternative SOC pathway in tumor-associated cells. These 
data also confirm that BTP2 selectively targets SOCE as 
TRPC3 and TRPC5, that could be inhibited by this drug 
in heterologous expression systems [36], are absent in BC-
ECFCs. Likewise, BC-ECFCs lack diacylglycerol-gated 
Ca2+-permeable channels, such as TRPC3, TRPC6 and 
TRPC7, which consists with our previous findings in N- 
and RCC-ECFCs [24].
The pharmacological blockade of SOCE 
inhibits BC-ECFC proliferation and 
in vitro tubulogenesis
The observation that VEGF does not stimulate 
proliferation and tube formation in BC-ECFC leads to the 
quest for alternative targets to halt BC vascularization. 
Our previous work provided the evidence that SOCE 
represents a druggable signalling pathway to inhibit the 
angiogenic activity of tumor-associated ECFCs [24, 25, 
Figure 12: Orai1, Stim1, TRPC1 and TRPC4 proteins are up-regulated in breast cancer-associated endothelial colony 
forming cells. Western blot and densitometry depicting the significant elevation in Orai1 (A), Stim1 (B), TRPC1 (C), and TRPC4 (D) 
proteins in BC-ECFCs as compared to N-ECFCs. Blots for Orai1, Stim1, TRPC1 and TRPC4 representative of 4 different experiments 
are shown in the lower panel. Lanes were loaded with 20 μg of proteins. Major bands of the expected molecular weight were observed in 
both cell types. One additional band of 77 kDa was detected by anti-Stim1 in RCC-EPCs. When both Stim1 bands (77 and 100 kDa) were 
compared to the single band detected at 100 kDa in N-ECFCs, the expression of Stim1 protein became significantly higher in BC-ECFCs. 
Each bar in the upper panel represents the mean±SE of the densitometric analysis of four different experiments. The asterisk indicates 
p<0.01 (Student's t-test).
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47]. Our recent study showed that there was no difference 
in either growth kinetics or tubulogenic rate between N- 
and BC-ECFCs cultured in EGM-2 [22]. Therefore, we 
first ascertained whether BC-ECFC proliferation was 
inhibited in BC-ECFCs cultured in EGM-2 supplemented 
with either of the following drugs: BAPTA (30 μM, 
1 hour), BTP2 (20 μM, 30 min), and La3+ (10 μM, 30 
min). As observed earlier for N-, RCC-, and IH-ECFCs, 
all of those treatments also prevented BC-ECFCs from 
reaching confluence at 5 days from plating (Figure 13A). 
Finally, we probed the effect of carboxyamidotriazole 
(CAI), a synthetic small molecule non-specific inhibitor 
of various types of Ca2+-permeable channels which 
hastens proliferation in BC endothelial cells [50] and 
RCC-ECFCs [24]. We first confirmed that CAI (10 μM, 
20 min) fully abolished both phases of the Ca2+ response 
to CPA (Figure 14A and Figure 14B) and ATP (Figure 
14C and Figure 14D). Then we found that CAI prevented 
VEGF-induced Ca2+ oscillations (Supplementary Figure 
3) and blocked proliferation in BC-ECFCs (Figure 13A). 
Furthermore, we found that BAPTA (30 μM, 1 hour), 
BTP2 (20 μM, 30 min), and CAI (10 μM, 20 min) also 
blocked in vitro tubulogenesis when BC-ECFCs were 
plated in Matrigel in the presence of the EGM-2 medium. 
Again, we evaluated both dimensional (total number of 
TLSs per picture) (Figure 13B) and topological (number 
of meshes per picture) (Figure 13C) parameters of the 
capillary-like network generated by BC-ECFCs plated 
in a Matrigel scaffold in the presence and the absence of 
the aforementioned drugs. Therefore, Ca2+ signalling in 
general and, particularly, SOCE could serve as a suitable 
target to dampen vascularization also in BC.
DISCUSSION
VEGFR2 has long been regarded as the most 
suitable target to interfere with tumor vascularization and 
increase OS in patients affected by highly angiogenic 
tumors, such as RCC and BC. The majority of in vitro 
studies which led to this assertion were, however, carried 
Figure 13: The pharmacological inhibition of store-operated Ca2+ entry blocks proliferation in breast cancer-derived 
endothelial colony forming cells. (A), BAPTA (30 μM, 2 hours), a membrane-permeable buffer of intracellular Ca2+ levels, BTP2 (20 
μM, 30 min), La3+ (10 μM, 30 min) and CAI (10 μM, 30 min) blocked proliferation in BC-ECFCs cultured in the presence of EGM-2. The 
asterisk indicates p<0.05. (B-C), statistical analysis of the dimensional (total TLSs per picture) and topological (total number of junctions 
between adjacent TLS and total number of meshes per picture) parameters of the capillary-like networks established by BC-ECFCs plated 
in Matrigel scaffolds in the presence and absence of BAPTA (30 μM, 2 hours), BTP2 (20 μM, 30 min), and CAI (10 μM, 30 min). In vitro 
angiogenesis was stimulated by plating the cells in the presence of EGM-2, while the EBM-2 medium (which is devoid of growth factors) 
was used as a control. The results are representative of three different experiments conducted on cells derived from three different donors. 
The asterisk indicates p<0.05.
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out on normal endothelial cell lines, such as human 
umbilical vein endothelial cells (HUVECs) and human 
dermal microvascular endothelial cell (HMVECs-D) 
[24]. Herein, we took advantage from the availability of 
patients-derived cells to assess whether VEGF stimulates 
proliferation in ECFCs, which are likely to support the 
angiogenic switch during BC development [19–21]. 
Our results provide the first evidence that ECFCs, 
which contribute to the angiogenic switch in BC [19, 
21], are insensitive to VEGF due to the attenuation of 
pro-angiogenic intracellular Ca2+ oscillations that arise 
upon VEGFR-2 activation in normal cells. These results 
may help to understand the cellular and molecular 
underpinnings of primary and secondary refractoriness of 
BC patients to anti-VEGF therapies.
In stringent disagreement with the traditional 
assumption [6, 51], VEGF was unable to stimulate 
proliferation and tube formation in BC-ECFCs. This 
feature was not due to the downregulation of VEGFR2, 
the receptor isoform that mediates its pro-angiogenic 
effect also in ECFCs [52], and suggested that the 
signalling pathways downstream VEGFR2 could 
be silenced/suppressed in tumor-associated ECFCs. 
Intracellular Ca2+ oscillations represent the main mode 
whereby growth factors stimulate angiogenesis in both 
mature endothelial cells [38, 39] and their more immature 
precursors [28, 29]. An increase in [Ca2+]i represents a 
central hub in the sophisticated network of interconnected 
signalling pathways that are recruited following VEGFR2 
stimulation. For instance, intracellular Ca2+ oscillations 
deliver the most effective signal to engage the Ca2+-
dependent transcription factors, NF-κB and nuclear factor 
of activated T cells (NFAT), which play a key role in 
VEGF-induced ECFC proliferation [28, 53], extracellular 
signal-regulated kinase (ERK), and phosphatidyl inositol 
3-kinase (PI3K)/Akt/protein kinase B [54], following 
VEGF stimulation. Our Ca2+ imaging recordings revealed 
that VEGF-induced intracellular Ca2+ oscillations were 
dramatically down-regulated in BC-ECFCs as compared 
to healthy cells. This observation is fully consistent with 
the results obtained from other types of tumor-associated 
ECFCs. Accordingly, VEGF failed to induce detectable 
Ca2+ spikes in RCC- and IH-ECFCs [24, 25], although 
VEGFR2 was normally expressed in these cells. Similarly, 
VEGF-induced Ca2+ oscillations were rather weak in 
ECFCs isolated from individuals affected from PMF [26], 
a chronic myeloproliferative neoplasm that is characterized 
by the development of a robust vascular network in both 
the bone marrow and spleen. Interestingly, VEGF failed 
to induce proliferation and tube formation also in these 
cells, a finding that has been invoked to explain the failure 
of anti-VEGF in this disease [13, 26, 34]. We, therefore, 
suggest that the weaker Ca2+ burst induced by VEGF in 
BC-ECFCs and PMF-ECFCs as compared to N-ECFCs 
Figure 14: Carboxyamidotriazole suppresses intracellular Ca2+ signalling in endothelial progenitor cells. (A), CAI (10 
μM, 20 min) abolishes the Ca2+ response to CPA (10 μM) in BC-ECFCs. (B), mean±SE of the amplitude of CPA-induced intracellular Ca2+ 
release and SOCE in BC-ECFCs. (C), CAI (10 μM, 20 min) abolishes the Ca2+ response to ATP (100 μM) in BC-ECFCs. B, mean±SE of 
the amplitude of ATP-induced intracellular Ca2+ release and SOCE in BC-ECFCs. The asterisk indicates p<0.05.
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does not reach the threshold of activation of endothelial 
Ca2+-dependent pro-angiogenic transcription factors, such 
as NF-κB and NFAT.
The down-regulation of VEGF-induced intracellular 
Ca2+ oscillations could depend on the recruitment of 
signalling components other than those at work in 
N-ECFCs [26] or on the remodelling of the Ca2+ toolkit 
[24, 25, 35]. However, the following pieces of evidence 
confirmed that the PLCγ/InsP3/SOCE signalling pathway 
was engaged by VEGF also in BC-ECFCs. First, the Ca2+ 
signal arose in the absence of extracellular Ca2+, which 
indicated that the Ca2+ response was driven by intracellular 
Ca2+ mobilization rather than Ca2+ entry, as described in 
PMF-ECFCs [26]. Second, the pharmacological blockade 
of PLCγ with U73122 or of InsP3Rs with 2-APB abrogated 
the onset of the Ca2+ spikes. Third, the pharmacological 
blockade of SOCE with BTP2 mimicked the effect of 
0Ca2+ by curtailing the duration of the Ca2+ train without 
preventing its onset. Unlike 0Ca2+ conditions, however, 
BTP2 did not delay the onset of the 1st Ca2+ spike. This 
apparent discrepancy could be explained by anticipating 
that BTP does not fully abrogate SOCE in BC-ECFCs 
(see Figure 7). We hypothesize that SOCE represents the 
source of Ca2+ necessary to sensitize InsP3Rs to PLCγ-
derived InsP3, by acting either on the luminal or the 
cytosolic side [55, 56], thereby regulating the latency of 
the 1st Ca2+ spike. If BTP2 does not fully abrogate SOCE, 
then some extremely localized Ca2+ influx is predict to 
occur in proximity of InsP3Rs and maintain the latency of 
the signal unaltered. Obviously, no Ca2+ entry occurs in the 
absence of external Ca2+, which could lead to a significant 
delay in the onset of the oscillations.
Based on the evidences illustrated above, the most 
likely interpretation to account for the attenuation of the 
pro-angiogenic Ca2+ oscillations was the remodelling 
of the Ca2+ toolkit in BC-ECFCs. This phenomenon 
has recently been proposed to underlie the resistance 
to chemotherapy and radiation therapy in both tumor 
cells [57, 58] and tumor-associated ECFCs [23, 34]. For 
instance, the reduction in ER Ca2+ concentration ([Ca2+]ER) 
and the hypo-expression of InsP3Rs prevent VEGF from 
triggering robust Ca2+ spikes in RCC-ECFCs [24, 35]. 
Our Ca2+ imaging recordings revealed that the ER Ca2+ 
pool was reduced also in BC-ECFCs. Accordingly, 
CPA-induced intracellular Ca2+ release was significantly 
dampened as compared to healthy cells. CPA, as well as 
its structurally unrelated analogue, thapsigargin, unmasks 
the physiological Ca2+ leakage through ER membrane 
by inhibiting SERCA-mediated Ca2+ sequestration, 
thereby leading to the rapid depletion of the ER Ca2+ 
pool. Previously, we exploited this strategy to show that 
ER Ca2+ levels were decreased in RCC-, IH-, and PMF-
ECFCs [24, 25, 47]. Notably, the chronic underfilling of 
ER in tumor-associated ECFCs was confirmed by directly 
measuring [Ca2+]ER through recombinant ER-targeted 
aequorin [35, 59]. This observation was further supported 
by the finding that InsP3-dependent Ca
2+ release, which 
was monitored by challenging the cells with the InsP3-
synthesizing autacoid ATP [24, 44], was also smaller in 
BC-ECFCs, while InsP3Rs were normally expressed. On 
the other hand, there was no difference in the amplitude 
and molecular composition of SOCE between N- and 
BC-ECFCs. Consistently, there was no difference in the 
expression profile of Orai1 and TRPC1, which provide 
the Ca2+-permeable routes on the plasma membrane 
gated following ER depletion, between N- and BC-
ECFCs. The overexpression of Stim1, which functions 
as the sensor of [Ca2+]ER and activates SOCs, was not 
sufficient to enhance SOCE in the latter, as previously 
shown in human salivary gland cells [60]. This feature 
confirms that Orai1 and TRPC1 represent the two limiting 
structural components of the SOCE machinery and that 
a correct stoichiometric expression of Stim1, Orai1 and 
TRPC1 is necessary for full SOCE activation in ECFCs 
[37, 61]. Moreover, SOCE was inhibited by BTP2 and 
10 μM La3+, which block SOCs contributed by Orai1 and 
TRPC1 in a growing number of cell types [36, 62–65], 
including tumor-associated ECFCs [24, 25]. Unlike IH-
ECFCs [25], pre-incubating the cells with either BTP2 or 
La3+ did not cause the depletion of the InsP3-sensitive ER 
Ca2+ pool. This result suggests that SOCE is not, or just 
minimally, activated under resting conditions and requires 
agonist-induced ER depletion to arise. Altogether, these 
observations strongly suggest that the down-regulation of 
VEGF-induced Ca2+ oscillations is due to the reduction in 
[Ca2+]ER, which prevents InsP3 from triggering the dynamic 
interaction between InsP3-dependent Ca
2+ release and 
SOCE which reliably engages the Ca2+-dependent pro-
angiogenic genetic program in N-ECFCs. The drop in ER 
Ca2+ levels could be due to the up-regulation of TMTC1 
recently reported in BC-ECFCs [22]. TMTC1 is a novel 
ER-resident tetratricopeptide repeat-containing adapter 
protein that binds to SERCA2B to curb its activity [66]. 
It has been shown that over-expression of TMTC1 in 
HEK293T caused a strong reduction in acetylcholine- and 
ionomycin-induced intracellular Ca2+ mobilization [66]. 
Although this hypothesis remains to be experimentally 
probed, we speculate that the increase in TMTC1 levels 
leads to the chronic Ca2+ underfilling of ER in BC-ECFCs. 
Likewise, future work will have to address whether 
lysosomal Ca2+ signalling contributes to VEGF-induced 
intracellular Ca2+ oscillations and is dysregulated in BC-
ECFCs. Accordingly, nicotinic acid adenine dinucleotide 
phosphate (NAADP) has been recently shown to underpin 
VEGF-induced endothelial Ca2+ signals and neo-
angiogenesis in melanoma [67]. An NAADP-sensitive 
lysosomal Ca2+ store is also present in N-ECFCs [30, 68], 
although it is seemingly down-regulated in BC-ECFCs 
(unpublished observations from our group).
As widely discussed elsewhere [13, 23], ECFC 
insensitivity to VEGF could contribute to the resistance 
to anti-VEGF therapies observed in cancer patients. 
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Accordingly, ECFCs resident within the vascular “stem 
cell niches” provide the building blocks for neovessel 
formation in growing tumors. Additionally, ECFCs 
paracrinally may boost angiogenesis by releasing a myriad 
of growth factors and cytokines that stimulate endothelial 
cells to undergo angiogenesis [13, 16–21, 69, 70]. Limited 
evidence has been provided to show that human TECs 
require VEGF for proliferation, survival and migration 
[20, 71–73], while only one study revealed VEGF-induced 
Ca2+ signals in B-TECs [72]. In the clinical practice, 
anti-VEGF inhibitors are administered as adjuvant for 
standard chemotherapy or radiation therapy when tumor 
vasculature has already been established. At this stage, 
ECFCs have already been diluted/replaced by endothelial 
cells sprouting from neighbouring capillaries and B-TEC 
mainly derive from VEGF-sensitive cancer stem cells 
or adjoining sprouting capillaries [12, 74–76]. It turns 
out that tumor blood vessels, which are mainly lined by 
VEGF-sensitive B-TECs, regress in the presence of anti-
angiogenic inhibitors. We hypothesize that the consequent 
dismantling of tumor vasculature exacerbates the hypoxic 
conditions of tumor microenvironment, thereby boosting 
the activation of hypoxia-inducible factors (HIFs) and 
inducing a second wave of ECFC mobilization [23]. 
Consequently, circulating ECFCs will be again recruited to 
the tumor site, in which they will be able to proliferate and 
re-establish the vascular network in spite of the presence 
of anti-VEGF drugs as they are not sensitive to VEGF 
[13, 23]. Although this scenario remains speculative and 
does not rule out the contribution of other mechanisms 
to the development of acquired refractoriness, including 
VEGFR2 downregulation in B-TECs [77], it could 
explain the limited increase in OS and PFS observed 
in BC patients treated with anti-angiogenic inhibitors. 
Unfortunately, no study has hitherto assessed the impact 
of anti-VEGF drugs on ECFC frequency either in BC or 
in any other tumor type. Of note, earlier studies showed 
that the systemic administration of bevacizumab caused an 
increase in the frequency of CD45dim, CD133+, VEGFR2+ 
EPCs in BC patients not responding to the therapy, while 
a reduction could not always be observed in those who 
did not show any change in disease progression [78]. 
Likewise, there was no significant relationship between 
the frequency of CD45–, CD133+/CD34+_EPCs and 
the therapeutic outcome of bevacizumab in BC patients 
enrolled in another study [79].
If VEGF does not stimulate BC-ECFC proliferation 
and tube formation, VEGFR2 cannot serve as a suitable 
target to prevent or interfere with BC vascularization. 
Nevertheless, the finding that the pharmacological 
blockade of SOCE with either BTP2 or 10 μM La3+ 
suppresses BC-ECFC growth and in vitro tubulogenesis 
provides further hints at SOCE as a promising candidate 
to develop alternative treatments to treat BC [36, 80]. 
Several studies showed that SOCE drives proliferation 
and migration also in several BC cell lines [43, 81, 82]. 
Therefore, SOCE stands out as a very attractive target 
to simultaneously halt BC cell growth and prevent 
ECFC activation at the tumor site [23, 33]. It would be 
interesting to assess whether SOCE controls proliferation 
(or migration) also in B-TECs, in which only store-
independent Ca2+ pathways have hitherto been described 
[72, 83]. The rationale to include SOCE among the most 
promising molecular anti-cancer targets has been provided 
by pre-clinical and clinical studies conducted on CAI. CAI 
is a non-specific synthetic blocker of various types of Ca2+ 
channels, including InsP3Rs, TRP channels, SOCs, and 
the mitochondrial Ca2+ uniporter [33, 84]. CAI suppresses 
a multitude of Ca2+-dependent signalling pathways and 
has been validated as an effective anti-tumor agent due 
to its ability to inhibit angiogenesis as well as tumor 
development, migration and metastasis [33]. Preliminary 
studies revealed that CAI also blocked proliferation and/or 
migration in several human BC cell lines and in B-TECs 
[85]. Previous work from our group confirmed that CAI 
prevented N- and RCC-ECFC proliferation and in vitro 
tubulogenesis by interfering with both ER-dependent 
Ca2+ release and SOCE activation [24]. The present 
results extend these observations by showing that CAI 
interferes with intracellular Ca2+ signalling and inhibits 
both growth and tube formation also in BC-ECFCs. Of 
note, CAI represents the sole Ca2+ antagonist currently 
under investigation as an orally administered tumoristatic 
and anti-angiogenic agent in clinical phase I-III trials of 
several solid cancers (http://clinicaltrials.gov/). Future 
work will have to assess whether CAI is capable of halting 
BC vascularization and causing tumor shrinkage also in 
preclinical models.
In conclusion, we provided the first clear-cut 
evidence that VEGF does not stimulate angiogenesis 
in ECFCs isolated from peripheral blood of metastatic 
BC patients. Several authors proposed that the acquired 
resistance to anti-VEGF therapy could result from the 
recruitment of vascular progenitor cells and myeloid 
cells from their bone marrow/vascular niches, which may 
obviate the necessity of VEGF signalling [7, 8, 11, 23, 
86]. Therefore, our data further corroborate the notion 
that tumor-associated ECFCs are insensitive to VEGF and 
lend the first strong cellular and molecular support to the 
notion that VEGFR2 is unlikely to be the most suitable 
target to halt vascularization and prevent tumor relapse 
in BC patients. VEGF fails to stimulate proliferation in 
BC-ECFCs due to the down-regulation of the intracellular 
Ca2+ spikes arising in normal cells following VEGFR-2 
activation. The dramatic reduction in ER Ca2+ content is 
a key determinant to prevent VEGF from triggering the 
periodic InsP3-depedent Ca
2+ release that underlies the Ca2+ 
train. This feature further suggests that the remodelling 
of the Ca2+ toolkit stands out as a crucial player in the 
development of the refractoriness to anti-cancer treatments 
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[23, 57, 58]. Targeting the intracellular Ca2+ machinery 
could represent an alternative, yet promising strategy to 
overcome the resistance to anti-angiogenic therapies and 
prevent tumor vascularization. In this view, SOCE is 
emerging as an attractive candidate to design innovative 
approaches to treat BC patients as it controls proliferation 
in both BC cells and BC-ECFCs, as shown by the present 
investigation.
MATERIALS AND METHODS
Isolation and cultivation of ECFCs
Blood samples (40 mL) were obtained from 
patients who were out of ongoing cytoreductive therapy 
at the moment of blood sampling for ECFC isolation 
and from healthy donors. The ECFC samples used in 
the present investigation belong to the stocks recently 
described and characterized in [22]. To isolate ECFCs, 
mononuclear cells (MNCs) were separated from 
peripheral blood by density gradient centrifugation on 
lymphocyte separation medium for 30 min at 400g and 
washed twice in endothelial basal medium-2 (EBM-2) 
with 2% foetal bovine serum (FBS). A median of 36 x 
106 MNCs (range 18-66) were plated on collagen-coated 
culture dishes (BD Biosciences) in the presence of the 
endothelial cell growth medium EGM-2 MV Bullet 
Kit (Lonza) containing EBM-2, 5% FBS, recombinant 
human (rh) EGF, rhVEGF, rhFGF-B, rhIGF-1, ascorbic 
acid and heparin, and maintained at 37°C in 5% CO2 and 
humidified atmosphere. Discard of non-adherent cells was 
performed after 2 days; thereafter medium was changed 
three times a week. The outgrowth of endothelial colonies 
from adherent MNCs was characterized by the formation 
of a cluster of cobblestone-appearing cells, resembling 
endothelial cells. That ECFCs-derived colonies belonged 
to endothelial lineage was confirmed as described in 
[22, 87]. In more detail, ECFCs-derived colonies were 
stained with anti-CD31, anti-CD105, anti-CD144, anti-
CD146, anti-von Willebrand factor (vWF), anti-CD45, 
and anti-CD14 monoclonal antibodies and by assessment 
of capillary-like network formation in an in vitro Matrigel 
assay. For our experiments, we have mainly used 
endothelial cells obtained from early passage ECFCs (P1-
3, which roughly encompasses a 15-18 day period) with 
the purpose to avoid (or maximally reduce) any potential 
bias due to possible cell differentiation. As already show 
in [24], the immunophenotype of both normal and tumor 
ECFCs does not change at different passages in culture. 
We also tested whether functional differences occurred 
when early (P2) and late (P6) passage-ECFCs were 
used by testing the in vitro capacity of capillary network 
formation in a Matrigel assay and found no differences 
between early and late passage ECFC-derived cells (data 
not shown).
Solutions
Physiological salt solution (PSS) had the following 
composition (in mM): 150 NaCl, 6 KCl, 1.5 CaCl2, 1 
MgCl2, 10 Glucose, 10 Hepes. In Ca
2+-free solution 
(0Ca2+), Ca2+ was substituted with 2 mM NaCl, and 0.5 
mM EGTA was added. Solutions were titrated to pH 7.4 
with NaOH. The osmolality of PSS as measured with an 
osmometer (Wescor 5500, Logan, UT) was 338 mmol/kg.
Electron microscopy
ECFCs were fixed with 2% paraformaldehyde and 
2.5% glutaraldehyde (Sigma–Aldrich) in 0.1 M sodium 
phosphate buffer, pH 7.4, as described in [35]. After 
fixation, cells were postfixed in 2% osmium (OsO4) for 1 
h at room temperature, dehydrated, and embedded in LR 
White (Sigma–Aldrich). Polymerization was performed 
for 24 h at 60°C. Ultrathin sections were cut with a 
Reichert (Depew, New York) OM-U3 ultramicrotome. 
The sections were stained with uranyl acetate and lead 
citrate (Sigma–Aldrich), examined and photographed 
at 3000×, 7.000×, or 20.000× magnifications on a Zeiss 
(Jena, Germany) EM900 (80 kV, objective diaphragm 30 
μm) electron microscope.
Flow cytometry
Early passage ECFCs were isolated by trypsinization 
and resuspended in EBM2 medium (Lonza, Basel CH) 
supplemented with 10% FBS, as described in [88]. ECFC-
derived cells (1x105 cells) were incubated with 5 μl of 
phycoerythrin (PE)-conjugated isotype control (IgG1) (BD 
Biosciences, San Josè, CA, USA) or 5 μl of PE-conjugated 
anti- VEGFR-2 antibody (R&D Systems, Inc Minneapolis, 
MN, USA) for 30 minutes at 4°C. ECFCs were than 
washed and resuspended in PBS with 1% FBS. Cells 
were aquired by a flow cytometer (NaviosTM; Beckman 
Coulter, Inc, Brea, CA) and analyzed by Kaluza® flow 
analysis software (Beckman Coulter). The number of 
dead/apoptotic cells was negligible, therefore the analysis 
was performed excluding cellular debris in a side scatter/
forward scatter dot plot.
[Ca2+]i measurements and statistical analysis of 
Ca2+ signals
ECFCs were loaded with 4 μM fura-2 acetoxymethyl 
ester (fura-2/AM; 1 mM stock in dimethyl sulfoxide) in 
PSS for 1 hour at room temperature. After washing in PSS, 
the coverslip was fixed to the bottom of a Petri dish and 
the cells observed by an upright epifluorescence Axiolab 
microscope (Carl Zeiss, Oberkochen, Germany), usually 
equipped with a Zeiss ×40 Achroplan objective (water-
immersion, 2.0 mm working distance, 0.9 numerical 
aperture). ECFCs were excited alternately at 340 and 380 
nm, and the emitted light was detected at 510 nm. A first 
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neutral density filter (1 or 0.3 optical density) reduced 
the overall intensity of the excitation light and a second 
neutral density filter (optical density=0.3) was coupled 
to the 380 nm filter to approach the intensity of the 340 
nm light. A round diaphragm was used to increase the 
contrast. The excitation filters were mounted on a filter 
wheel (Lambda 10, Sutter Instrument, Novato, CA, USA). 
Custom software, working in the LINUX environment, 
was used to drive the camera (Extended-ISIS Camera, 
Photonic Science, Millham, UK) and the filter wheel, and 
to measure and plot on-line the fluorescence from 10 up 
to100 rectangular “regions of interest” (ROI). Each ROI 
was identified by a number. Since cell borders were not 
clearly identifiable, a ROI may not include the whole cell 
or may include part of an adjacent cell. Adjacent ROIs 
never superimposed. [Ca2+]i was monitored by measuring, 
for each ROI, the ratio of the mean fluorescence emitted 
at 510 nm when exciting alternatively at 340 and 380 nm 
(shortly termed “ratio”). An increase in [Ca2+]i causes 
an increase in the ratio [87]. Ratio measurements were 
performed and plotted on-line every 3 s. The experiments 
were performed at room temperature (22°C).
All the data have been collected ECFCs isolated 
from three different healthy donors. VEGF-induced 
intracellular Ca2+ oscillations were analysed by evaluating: 
1) the latency before the onset of the pacemaker potential 
leading to the first regenerative Ca2+ spike; 2) the 
amplitude of the first Ca2+ spike (which was calculated as 
the difference as the ratio at the peak and the mean ratio 
of 1 min baseline before the slow pacemaker potential); 
3) the number of Ca2+ spikes during 1 hour recording. The 
amplitude of the peak Ca2+ response to CPA and ATP was 
measured as the difference between the ratio at the peak 
(either of intracellular Ca2+ mobilization in 0Ca2+ or of 
Ca2+ entry occurring upon Ca2+ restoration to the bath) and 
the mean ratio of 1 min baseline before the peak. Pooled 
data are given as mean±SE and statistical significance 
(p<0.05) was evaluated by the Student’s t test for unpaired 
observations.
Wavelet analysis of Ca2+ signals
To give a quantitative evaluation of the differences 
in Ca2+ oscillatory activity between N- and BC-ECFCs 
after VEGF administration, an approach based on wavelet 
analysis was employed, using KYM 0.5 software (http://
sourceforge.net/projects/kym/) as presented in [26, 39, 
40]. Briefly, the wavelet transform W(a,b) = |a|-1/2 ∫ ψ*[(t 
– b)/a] f(t) dt was computed for each calcium trace using 
Morlet function ψ(t) ≈ π-1/4 exp(–0.5 t2) exp(ist) as mother 
wavelet, then, after having renamed b as t and having 
done the substitution ν = s/(2πa), the activity index J(t) 
≈ ∫ |W(t,ν)|2 ν dν was calculated according to equations 
3,4,5 and 9 of [40]. Notably, weighting wavelet transform 
modulus by the frequency, J keeps into account both the 
amplitudes and the values of the frequency components 
making up the oscillatory signal. Activity index has been 
evaluated for each calcium trace as a function of time, then 
its time-averaged value <J> has been calculated for each 
cell thus allowing to statistically compare the two <J> 
mean values representative of the two group of interest 
(N- and BC-ECFCs).
RNA isolation and qRT-PCR
Total RNA was extracted from N- and BC-ECFCs 
by using the QIAzol Lysis Reagent (QIAGEN, Italy). 
Single cDNA was synthesized from RNA (1 μg) using 
random hexamers and M-MLV Reverse Transcriptase 
(Invitrogen S.R.L., Italy). Reverse transcription was 
always performed in the presence or absence (negative 
control) of the reverse transcriptase enzyme. qRT-PCR 
was performed in triplicate using 1 μg cDNA and specific 
primers (intron-spanning primers) for Stim1-2, Orai1-3, 
TRPC1-7, and InsP3Rs1-3, as previously described [24, 
47] (Supplementary Tables 1-2). Briefly, GoTaq qPCR 
Mastermix (Promega, Italy) was used according to the 
manufacturer instruction and qRT-PCR performed using 
Rotor Gene 6000 (Corbett, Concorde, NSW, Australia). 
The conditions were as follows: initial denaturation at 
95°C for 5 min; 40 cycles of denaturation at 95°C for 
30 sec; annealing at 58°C for 30 sec, and elongation at 
72°C for 40 sec. The qRT-PCR reactions were normalized 
using β-actin as housekeeping gene. Melting curves were 
generated to detect the melting temperatures of specific 
products immediately after the PCR run. The triplicate 
threshold cycles (Ct) values for each sample were 
averaged resulting in mean Ct values for both the gene of 
interest and the housekeeping gene β-actin. The gene Ct 
values were then normalized to the housekeeping gene by 
taking the difference: ΔCt = Ct[gene] - Ct[β-actin], with 
high ΔCt values reflecting low mRNA expression levels. 
The sequences of the bands were checked by using the Big 
dye terminator cycle sequencing kit (Applied Biosystem, 
PE, USA). PCR products were also separated with agarose 
gel electrophoresis, stained with ethidium bromide, 
and acquired with the Image Master VDS (Amersham 
Biosciences Europe, Italy). The molecular weight of 
the PCR products was compared to the DNA molecular 
weight marker VIII (Roche Molecular Biochemicals, 
Italy).
Sample preparation and immunoblotting
ECFCs were homogenized by using a Dounce 
homogenizer in a solution containing: 250 mM Sucrose, 
1 mM EDTA, 10 mM Tris-HCl, pH 7.6, 0.1 mg/mL 
PMSF, 100 mM β-mercaptoethanol and Protease Inhibitor 
Cocktail (P8340, Sigma, USA). The homogenates 
were solubilized in LaemmLi buffer (Dragoni et al., 
2014) and 30 μg proteins were separated on 10% SDS-
polyacrilamide gel electrophoresis and transferred to the 
Hybond-P PVDF Membrane (GE Healthcare, Italy) by 
electroelution. After 1 h blocking with Tris buffered saline 
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(TBS) containing 3% BSA and 0.1% Tween (blocking 
solution), the membranes were incubated for 3 h at room 
temperature with the following affinity purified antibodies 
diluted 1:200 in the TBS and 0.1% Tween: anti-Stim1 
(sc-166840), anti-Orai1 (sc-68895), anti-TRPC1 (sc-
133076), anti-TRPC3/6/7 (sc-15056), and anti-IP3R-I/
II/III (sc-377518) from Santa Cruz Biotechnology, anti-
Orai3 (HPA015022), anti-Stim2 (PRS4123) from Sigma-
Aldrich (Italy), and anti β-actin rabbit antibody as control 
(Rockland Immunochemicals for Research, U.S.A.; 
code, 600-401-886). The membranes were washed and 
incubated for 1 h with peroxidase-conjugated mouse, 
rabbit or goat IgG (1:120000 in blocking solution), 
from Dakocytomation (P0260), Chemicon (AP132P), 
and Santa Cruz (sc-2354), respectively. The bands 
were detected with the ECL™ Select western blotting 
detection system (GE Healthcare Europe GmbH, Italy). 
Prestained molecular weight markers (SDS7B2, Sigma, 
Italy) were used to estimate the molecular weight of the 
bands. Control experiments were performed by using the 
antibody preadsorbed with a 20-fold molar excess of the 
immunizing peptide or by incubating the blots with non 
immune serum.
Protein content
Protein contents of all the samples were determined 
by the Bradford’s method using bovine serum albumin 
(BSA) as standard [24, 47].
Chemicals
EBM and EGM-2 were purchased from Clonetics 
(Cell System, St. Katharinen, Germany). Fura-2/AM 
was obtained from Molecular Probes (Molecular Probes 
Europe BV, Leiden, The Netherlands). BTP2 was 
purchased from Calbiochem (La Jolla, CA, USA). All 
other chemicals were obtained from Sigma Chemical Co. 
(St. Louis, MO, USA).
Proliferation assays
As described elsewhere [24, 87], growth kinetics 
were evaluated by plating a total of 1 x 105 ECFCs-derived 
cells (first passage) in 30-mm collagen-treated dishes in 
the presence of EBM-2 and 5% FBS supplemented with 10 
ng/mL VEGF and one of the either compounds: BAPTA 
(30 μM, 1 hour), BTP2 (20 μM, 30 min), La3+ (10 μM, 30 
min), or CAI (10 μM, 20 min). Cultures were incubated 
at 37°C (in 5% CO2 and humidified atmosphere) and cell 
growth assessed every day until confluence was reached 
in control cultures. At this point, cells were recovered 
by trypsinization from all dishes and the cell number 
assessed by counting in a haemocytometer. Preliminary 
experiments showed no unspecific or toxic effect for each 
agent when used at these concentrations. Each assay was 
repeated in triplicate.
In vitro tube formation assay
The tube formation assay was carried out as 
previously shown [26]. To evaluate the effect of VEGF, 
early passage (P2-P3) BC-ECFCs were detached by 
trypsinization and resuspended in EBM-2 supplemented 
with 2% FBS. ECFC-derived cells were plated at 1.5 x 104 
per well in Cultrex (Trevigen)-coated 96 well plates, in the 
presence of EBM-2 ± 10 ng/mL VEGF. Capillary network 
formation was assessed starting from 4 to 24 hours later. 
Three different sets of experiments, each performed in 
duplicate, were carried out. Experiments were repeated a 
minimum of three times and the vasculogenic response 
was measured by evaluating both dimensional and 
topological parameters. As illustrated in [26], we analyzed 
the length of endothelial tube-like structures (TLSs) and 
the number of the polygon structures established by TLSs, 
which are referred to as complex meshes and are indicative 
of endothelial cell migration. These analyses were 
performed by using the Angiogenesis Analyzer plugin 
of ImageJ (Gilles Carpentier, Faculte´ des Sciences et 
Technologie, Universite´ Paris Est, Creteil Val de Marne, 
France) [26]. To evaluate the effect of SOCE inhibitors, 
the same protocol was repeated by stimulating in vitro 
angiogenesis with the EGM-2 medium in the presence and 
absence of the following drugs: BAPTA (30 μM, 1 hour), 
BTP2 (20 μM, 30 min), or CAI (10 μM, 20 min).
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